The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients.

The drug release system, branded as Inlexzo, was approved for patients with a type of high-risk non-muscle invasive bladder cancer who did not respond to treatment with Bacillus Calmette-Guerin therapy, the current standard-of-care, and are ineligible for, or refuse to undergo bladder removal surgery.

“We believe Inlexzo represents a unique bladder-sparing treatment that addresses a significant unmet need for patients who have limited options after unsuccessful BCG therapy,” said Guggenheim analyst Vamil Divan. 3

Divan estimates potential revenue of about $3.4 billion for Inlexzo by 2040.

The approval was bas

See Full Page